The last 20 years have seen major progress in the treatment of relapsing-remitting multiple sclerosis (RRMS) using a variety of drugs targeting immune dysfunction. In contrast, all clinical trials of such agents in primary progressive multiple sclerosis (PPMS) have failed and there is limited evidence of their efficacy in secondary progressive disease. Evolving concepts of the complex interplay between inflammatory and neurodegenerative processes across the course of multiple sclerosis (MS) may explain this discrepancy. This paper will provide an up-to-date overview of the rationale and results of the published clinical trials that have sought to alter the trajectory of both primary and secondary MS, considering studies involving drugs with a primary immune target and also those aiming for neuroprotection. Future areas of study will be discussed, building on these results combined with the experience of treating RRMS and new concepts emerging from laboratory science and animal models.
Introduction
There is no other neurological disease in the last 20 years that can equal multiple sclerosis (MS) for progress in treatment. Since the publication in 1993 of the efficacy of interferon (IFN)β−1b in relapsing-remitting multiple sclerosis (RRMS), 1,2 there has been growing evidence that drugs with differing mechanisms of action which target the immunological changes leading to inflammation in the central nervous system (CNS) can variably reduce both clinical and magnetic resonance imaging (MRI) measures of disease activity. 3 Large effects on the relapse rate have usually been associated with a significant decrease in the risk of disability progression. [4] [5] [6] More recently, the concept of early treatment 7 has gained acceptance in the MS community after evidence that the same agents shown to be effective in the relapsing-remitting phase of the disease are also able to significantly delay the occurrence of a second attack in patients following a first demyelinating clinical episode. 8, 9 There is converging evidence that drugs used to treat RRMS patients have greater beneficial effects if used immediately after the first attack. 10 Soon after the efficacy of interferons in RRMS was demonstrated, clinical trials were started in secondary progressive multiple sclerosis (SPMS) in both North America and Europe. These clinical trials produced essentially negative results, with the exception of the European clinical trial on the effects of IFNβ−1b 11 and the MIMS trial exploring the effects of mitoxantrone. 12 All clinical trials performed in primary progressive multiple sclerosis (PPMS) have failed. The observation of a differing response to the same treatment in the different phases of MS provides clear evidence that pathophysiological mechanisms change along the course of the disease and calls for new therapeutic strategies for progressive disease. It is now considered that the progressive phase of MS is dominated by neurodegenerative phenomena, 13 at least partially determined by compartmentalized inflammation in the CNS driven by microglial activation. 14, 15 Brain MRI has recently contributed to a better understanding of the mechanisms underlying neurodegeneration in MS. Firstly, many studies using magnetization transfer ratio, diffusion tensor imaging and magnetic resonance spectroscopy have shown widespread changes in the so-called 'normal-appearing' tissues of the brain and spinal cord in the white, and especially gray, matter of progressive MS patients. [16] [17] [18] Such changes may be explained by a diffuse neurodegenerative process, however it has recently been demonstrated that anterograde and retrograde degeneration of interconnected brain areas 19, 20 may also play a role. Secondly, gray matter damage plays an important role in the accumulation of disability in the progressive phase 21, 22 and the number of cortical lesions increases at a significantly greater rate in patients with actively progressive disease, correlating with increasing Expanded Disability Status Scale (EDSS) score and cognitive dysfunction. 23, 24 Among the three types of cortical lesions, subpial lesions are the most frequent and can be very extensive, affecting >60% of the cortical ribbon in the cerebrum, 25 cerebellum 26 and hippocampus. 27 This type of cortical lesion has been attributed to diffuse meningeal inflammation. These subpial lesions are quite frequent in progressive MS, 28, 29 sometimes organized in follicle-like structures in SPMS 30, 31 but not in PPMS, 29 and have also recently been reported to occur in early MS cases. 32 These observations suggest that both cortical lesions and meningeal inflammation play a role in increasing disability, although are not specific to the progressive phase of MS.
Links between the early inflammatory phase and late degenerative phase are not clear, however the exhaustion of remyelination processes, 33 the secondary degeneration of demyelinated axons due to abnormal axonal excitability 34 and mitochondrial failure 35 are probably contributing factors. Finally, it should be considered that the redundancy of the nervous system and its large plasticity may protect from functional impairment even in presence of significant tissue damage; however when a critical threshold is reached, even minor further damage may result in irreversible neurological abnormalities.
In Table 1 the key differences between progressive and relapsing MS are summarised.
In this review we will focus on the results of phase II-III clinical trials exploring disease modifying treatments for progressive MS with a few notes about future developments in this area. There is some evidence that, even though PPMS and SPMS have a similar evolution in the progressive phase 36 and a similar genetic basis, 37 they may differ in other aspects. 38 As such, we will discuss their treatment separately.
Anti-inflammatory treatments
SPMS. Two treatments have been approved for SPMS patients in Europe and North America: IFNß-1b 39 and mitoxantrone. 40 The European Trial in SPMS (EUSPMS), testing IFNβ−1b against placebo, recruited 718 patients. There was a 22% reduction in the proportion of patients with three months confirmed disability progression which was independent of baseline EDSS, pre-entry relapse rate and the occurrence of relapses during the study. There was a significant reduction in clinical and MRI activity, of the same magnitude observed in the pivotal clinical trial in RRMS. Unfortunately, a subsequent study performed in North America failed to confirm the effect of IFNβ-1b on disability progression, even if the efficacy on clinical and MRI measures of disease activity was confirmed. 41 A comparison between the two studies shows a younger and more active population in the EUSPMS trial, in line with a better response to anti-inflammatory treatments in patients with more active disease. Moreover, it is probable that a higher relapse rate on study may have driven the EDSS changesthe annualised relapse rate of 0.64 observed in the placebo arm of the EUSPMS trial is a value not observed even in pure RRMS clinical trials today.
Subcutaneous IFNβ-1a has been tested in two clinical trials in SPMS. In SPCTRIMS, a multicentre European, Canadian and Australian trial, 618 patients were randomised to placebo or two doses of IFNβ-1a, 22 or 44 μg s/c three times/wk. The risk of disability progression did not differ between treatment arms, however both doses significantly reduced the relapse rate and the number of active MRI lesions. 42 In a second trial performed in Northern European countries, the 22 μg dose was tested against placebo. Again, no effect on disability progression was seen. Moreover, in this study, there was no effect on annualised relapse rate; brain MRI was not performed. 43 Only one trial has been performed to explore the efficacy of intramuscular IFNβ-1a in SPMS, the IMPACT trial, showing no significant modification of the risk of disability progression despite a significant reduction in clinical relapse and MRI activity. 44 A recent Cochrane review has concluded that there is no effect of IFNs in reducing the risk of sustained six-month EDSS progression in SPMS patients, however there is a Table 1 . Key aspects of progressive multiple sclerosis distinguishing it from relapsing-remitting multiple sclerosis (RRMS).
• Time to disability progression is not driven by relapse rate, frequency or severity • Fewer gadolinium enhancing lesions (signifying fewer blood-brain barrier breaches) • Less peripheral immune cell activation • Compartmentalised inflammation within the central nervous system (CNS) • Fewer active plaques • Anti-inflammatory therapies less effective or ineffective • More atrophy, axonal loss and cortical pathology • Universal progressive spinal disease Table 2 . Drugs tested in phase III clinical trials in progressive mutliple sclerosis.
SPMS
• Cladribine
significant decrease of the risk of three-month confirmed disability progression, reflecting relapse-related disability changes. 45 Based on these results the clinical use of IFN in SPMS patients is restricted to the use of IFNβ−1b in patients with persisting attacks, mostly those with low levels of disability. The rationale for this is twofold: (a) these patients still have some level of ongoing inflammatory activity which may respond to the drug; (b) IFNs increase spasticity and the potential advantages of protection from new lesions are countered by adverse effects on the motor system.
Mitoxantrone is an anti-neoplastic anthracenedione derivative which inhibits DNA replication, DNA-dependent RNA synthesis and DNA repair, resulting in a marked reduction of B and T cell numbers. Mitoxantrone is a very small molecule, able to cross the blood-brain barrier and interact with cells in the CNS. 46, 47 The most important limitation in its use is its long-term safety, mainly related to the risk of cardiotoxicity and acute leukaemia. 48, 49 In the MIMS trial, 194 patients with worsening RRMS or SPMS were assigned placebo or mitoxantrone, 12 mg/m 2 intravenously every three months for 24 months. About half of the patients were classified as SPMS. At 24 months, the mitoxantrone group experienced benefit compared to the placebo group for disability progression confirmed at three and six months. 40 However, the proportion of patients who progressed overall was low (19% placebo vs 7% mitoxantrone) and a separate statistical analysis of the SPMS patients was not performed. Effects on the relapse rate and MRI parameters were positive in the mitoxantrone arm compared to placebo. The type of patients included in the MIMS trial does not allow conclusions to be drawn on the efficacy of mitoxantrone in SPMS patients without attacks. Interestingly, a recent open study comparing the efficacy of the drug in RRMS and SPMS showed a significantly higher proportion of patients free from disability progression in the RRMS group compared to the SPMS group, 50 in line with observations using IFNβ.
Other treatments have been tested in phase II-III clinical trial in SPMS patients or in mixed progressive MS populations, all with negative results (Tables 2 and 3 ). Glatiramer acetate (GA) showed no effects on disability in a study performed in 106 progressive MS patients. 51 The effect of high dose intravenous immunoglobulin (IVIg) was tested in two studies. In a large multicentre phase III clinical trial (ESIMS trial) no effect was seen on clinical and MRI measures of disease activity and disease burden, including brain atrophy. 52 In a second multicentre clinical trial in progressive MS patients (the vast majority SPMS), IVIg led to a significant reduction in the proportion of patients with confirmed disability progression, however some methodological aspects limit the value of the results. 53 Cyclophosphamide and methotrexate have been used for more than 30 years in progressive MS on the basis of marginal positive effects seen in old studies. [54] [55] [56] [57] [58] Patients in the early progressive phase with clinical and MRI evidence of persistent inflammatory activity seem to respond to this therapeutic approach. Cladribine is a powerful immunosuppressive agent, moderately effective in RRMS, 59 even if it has not been approved in the European Union and USA due to a presumed unfavourable safety profile. Cladribine has been tested in progressive MS in two phase III clinical trials. In the first trial, cladribine significantly reduced the risk of disability progression with a marked reduction of MRI activity. 60 In a second clinical trial, two doses of the drug were tested against placebo in a mixed population of PPMS and SPMS patients: no effects were observed on the primary end point, disability progression although, again, a marked reduction in MRI activity was evident. 61, 62 The small sample size and the short duration of the two trials, one year, along with the low proportion of patients with active disease in the second may partially explain the discrepancy between the results. Alemtuzumab is a humanized IgG1 monoclonal antibody targeting CD52, a glycoprotein expressed widely throughout the immune system on T and B lymphocytes, natural killer (NK) cells, dendritic cells, most monocytes and macrophages. 63 Two phase III clinical trials have shown a clear superiority versus IFNβ-1a sc in RRMS. 64, 65 In contrast, despite its profound effect in inhibiting the formation of active lesions on MRI, alemtuzumab did not halt the progression of disability or the development of brain atrophy in SPMS patients. 66 High-dose immunosuppressive regimens followed by autologous hematopoietic cell transplantation (AHCT) rescue is effective in controlling inflammatory activity in some autoimmune diseases including MS. 67 The effects of AHCT in progressive MS have been explored in many small uncontrolled studies which have consistently shown that when patients are treated in the advanced phase of the disease, the decline in neurological function continues even when there is little clinical and MRI evidence of ongoing inflammation. 68, 69 In a recent long-term follow-up report, disease progressionfree survival at 15 years was 44% for individuals with active CNS disease pre-transplant and only 10% for those without, 70 suggesting that even extreme immunosuppression fails if applied too late in the disease evolution.
Antibody targeting of myelin components may be important to disease progression, 71 so tolerization to one or more epitopes may be effective in MS. MBP8298 (dirucotide) is a synthetic peptide with an amino acid sequence corresponding to amino acids 82-98 of myelin basic protein (MBP). MBP8298 has been tested in a phase III clinical trial in SPMS with no effects seen on disability progression or disease activity. 72 PPMS. There are no approved treatments for PPMS. All phase III clinical trials have had negative results, even if the possibility of a positive effect on specific subgroups has emerged in post hoc analyses of some studies.
IFNβ has been tested in two clinical trials. In the first two-year study, IFNβ-1a i.m. was tested against placebo in a small group of 50 patients. 73 No significant effect emerged on the risk of confirmed disability progression or on the evolution of brain atrophy. In the second study, 73 PPMS patients were included in a double blind phase III clinical trial exploring the effects of IFNβ-1b against placebo. There was a trend towards a decrease in the proportion of patients with confirmed disability progression, from 38% in the placebo arm to 28% in the IFNβ-1b arm (-26%). There was a significant reduction in new T2 and new T1 lesions in the active treatment arm but no effect on brain or spinal cord atrophy. 74 The PROMiSe trial recruited 934 PPMS patients to evaluate the effects of GA versus placebo on disability. The study was terminated by the data safety monitoring committee for futility when more than two-thirds of the patients had completed at least two years. 75 No effects were observed on time to confirmed EDSS progression (hazard ratio 0.87). In a post hoc analysis there was a significant increase of time to disability progression in males treated with GA compared to males randomised to placebo (p=0.02) but no similar difference was seen in females.
Interestingly, the number of gadolinium (Gd)-enhancing lesions at year 1, but not at year 2, was also significantly decreased (p<0.005) and the increase in T2 lesion volume was significantly less in the GA arm at year 2. However, the T2 lesion volume change was significant in females only. 76 Rituximab, a B-cell depleting monoclonal antibody, was investigated in 439 patients with PPMS. 77 No significant effects were observed at the primary end point which was the time to confirmed disability progression. Pre-planned subgroup analysis revealed a significant prolongation in the time to disability progression in younger patients with active disease at entry revealed by the presence of Gd-enhancing lesions. The speed of disability progression was much faster in younger and baseline-active patients than in older and baseline-inactive patients. The efficacy of rituximab in this subgroup of patients may be explained by the strong anti-inflammatory effects of the drug, already seen in RRMS patients. 78 No effects were observed on brain atrophy, however brain volume changes in subgroups of patients were not reported. These observations are fully in line with what has been seen in SPMS: a dissociated effect of anti-inflammatory treatments on disease activity and disease progression.
Neuroprotective treatments
There are two main reasons why neuroprotective strategies may have a role in progressive MS: (a) mechanisms underlying the progressive phase of MS are at least partially independent from ongoing inflammation; (b) neuroprotection could be be combined with anti-inflammatory treatments. Neuroprotection is a very broad concept, including the preservation of the integrity of myelin, axons, neurons and glial cells.
Some drugs have been shown to be effective neuroprotective agents in different animal experimental autoimmune encephalomyelitis (EAE) models, but only very few have been tested in clinical MS. Erythropoietin (EPO) is an antiapoptotic and anti-oxidative agent that promotes neurite outgrowth, axonal repair, neurogenesis and angiogenesis. 79, 80 EPO increases functional recovery in EAE. 81 In MS, initial signs 82 of a possible effect on disability progression and cognition were not followed by further investigations. In a small pilot trial in 16 patients with PPMS the glutamate-antagonist riluzole showed neuroprotective effects on MRI parameters, revealing a stabilization of T1-hypointense lesion volume and cervical cord area. 83 Another potentially neuroprotective drug is the sodium and calcium channel blocker, lamotrigine. Excessive accumulation of sodium ions may occur in axons affected by inflammation or demyelination, which might make these axons vulnerable to injury by favouring calcium accumulation through the sodium-calcium exchanger. 84 Partial blockade of voltage-gated sodium channels may result in a neuroprotective effect, as suggested by observations in both EAE and other experimental models of inflammatory axonal injury. 85, 86 In a phase II clinical trial of lamotrigine, brain atrophy, the primary end point of the study, progressed at a similar annual rate in the active and placebo arms. 87 No significant effect of lamotrigine was seen on spinal cord atrophy or on MRI measures of disease activity and disease burden.
Recently, preliminary results of a phase II clinical trial on the effects of simvastatin in patients with SPMS have been presented. 88 Confirmed disability progression and the rate of brain atrophy were both significantly reduced by simvastatin compared to placebo. This surprising result, considering the previously negative results of a clinical trial with statins in progressive MS, needs to be confirmed by larger studies.
In addition to these protective strategies targeted directly at the neurones, it might be possible to promote neuroprotection indirectly through manipulation of the innate immune system. Cells playing a direct or indirect role in the innate immune system, such as activated microglia, dendritic cells and astrocytes are recognised to have a role in the mechanisms of progression. Some drugs, such as sphingosine-1-phosphate agonists, laquinimod, fumarate, natalizumab and ocrelizumab which have already demonstrated a significant anti-inflammatory effect are now being tested, or are under consideration to be tested, in phase II-III clinical trials in progressive MS patients. Some other drugs, such as minocycline, which have failed in RRMS, have revealed effects on disease progression in EAE models. 89 The ability to prevent disease progression in PPMS and SPMS is also being evaluated for cannabis extracts based on the observation that the activation of the cannabinoid receptor type 1 results in some degree of neuroprotection, slowing down the atrophy associated with EAE 90 and decreasing microglia-mediated nervous tissue damage. 91 Moreover, a role for cannabinoids is further suggested by the report of Rossi et al. 92 that MS patients homozygous for long AAT repeats in the cannabinoid CB1 receptor gene have more severe disease and a higher risk of disease progression. In a follow-up for up to 12 months of the main Cannabinoids in Multiple Sclerosis (CAMS) study, there was marginal evidence for a treatment effect of Δ9-tetrahydrocannabinol on some aspects of disability. The short duration of the trial limited the value of the observation which nevertheless encouraged further study of the cannabinoids in progressive MS. Very recently, 93 in a doubleblind, placebo-controlled, multicentre phase III clinical trial, the CUPID study, oral dronabinol (Δ9 tetrahydrocannabinol) had no effect on EDSS progression in patients with progressive MS. No effects were also observed on other measures of disability, quality of life or brain atrophy.
Mesenchymal stem cells are pluripotent cells that can be derived and expanded from various adult tissues (e.g. bone marrow or adipose tissue) or fetal tissue (e.g. placenta) and can differentiate into cells of mesodermal origin (e.g. bone, cartilage or fat). The potential role of mesenchymal stem cells for neuroprotection in multiple sclerosis has been reviewed. [94] [95] [96] The recent evidence of an improvement in visual function in 10 SPMS patients included in an open label, phase IIa proof-of-concept study using autologous mesenchymal stem cells is of great importance, not only because it is the first evidence of the possibility to enhance repair, but also because of the demonstration that, with appropriate biomarkers, it is possible to discriminate neuroprotective properties of a treatment. 97 Another three open label studies [98] [99] [100] provide some evidence of efficacy on clinical and MRI parameters, however the small number of patients recruited and the weakness of the study design make these results essentially anecdotal. A multicentre, multinational, phase II, double-blind, randomised, crossover trial has recently started to evaluate the safety and efficacy of these cells in active RR and progressive MS patients. 101 Another exciting approach is to promote remyelination in order to prevent axonal loss. It is beyond the scope of this review to discuss fully strategies to promote/improve remyelination with chemical or cellular approaches. The reasons why remyelination is impaired in MS are not completely understood, but one likely mechanism is the inhibition of oligodendrocyte precursor cells within chronic MS plaques. 102, 103 Proteomic analysis of chronic plaques (e.g. Han et al. 104 ) will be important to identify the factors that block oligodendrocyte differentiation. One key factor that has already been identified is LINGO-1 (leucine-rich repeat and Ig-like domain-containing Nogo receptor-interacting protein 1). LINGO-1 antagonism has recently shown the potential to enhance remyelination. 105 Phase II clinical trials are ongoing to test the neuroprotective and remyelination effects of a monoclonal antibody against LINGO-1. 106 
Conclusions
In contrast to the advances in the treatment of relapsing MS, which have positively influenced the lives of patients in the early and intermediate phase of the disease, almost nothing has been achieved in the treatment of patients who have the progressive form of the disease. The major reason for this failure is that most, if not all, treatments tested in progressive MS have had as their main target derangement of the immune system in the periphery, which is probably playing only a minor role in the accumulation of nerve tissue damage accumulated in the progressive phase. A better understanding of the pathophysiology of the progressive phase of the disease is central to the development of new treatments. We have learnt from treating RRMS that tackling pathological processes early in their evolution results in greater clinical benefit. In an analogous way, it is possible that treatment of progressive MS with appropriate interventions targeting the specific pathogenic mechanisms of progression (potentially alterations in innate immunity) should be started very early, probably in the relapsing phase of the disease, with a combination of drugs targeting both peripheral and the central immune dysfunction.
A recent initiative promoted by a concerted action of various national MS societies and supported by the International MS Federation, the MS Progressive Initiative, is committed to engage the MS research community through an international effort to fund a spectrum of research activities relevant to progressive MS with the ultimate goal of expediting the development of disease-modifying and symptom-relief treatments for this stage of the disease.
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